What Is Kisspeptin-10?
Kisspeptin-10 (KP-10) is classified as a reproductive peptide peptide. Endogenous neuropeptide that is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-10 binds to the GPR54 (KISS1R) receptor on GnRH neurons, triggering pulsatile GnRH release which stimulates LH and FSH secretion from the pituitary. This cascade drives testosterone production in males and ovulation in females. Unique advantage: activates the reproductive axis at its highest control point without bypassing natural feedback loops.
It is extensively evaluated in laboratory and clinical settings for its potential to drive lh/fsh stimulation, testosterone support, fertility enhancement, hpg axis activation. Researchers target Kisspeptin-10 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Endogenous human neuropeptide with growing clinical trial data. Tachyphylaxis (desensitization) occurs with continuous dosing; pulsatile/intermittent protocols required. Being investigated as a safer IVF trigger (vs. hCG). Not FDA-approved for therapeutic use. Research-only.
How Does Kisspeptin-10 Work?
Endogenous neuropeptide that is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-10 binds to the GPR54 (KISS1R) receptor on GnRH neurons, triggering pulsatile GnRH release which stimulates LH and FSH secretion from the pituitary. This cascade drives testosterone production in males and ovulation in females. Unique advantage: activates the reproductive axis at its highest control point without bypassing natural feedback loops.
At the molecular level, Kisspeptin-10 operates through pathways characteristic of the Reproductive Peptide class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with lh/fsh stimulation, testosterone support, fertility enhancement, hpg axis activation.
Expected Research Timeline
Weeks 2–4
Sustained testosterone elevation with pulsatile dosing; improved energy and mood; fertility markers improving
Months 2–3
Stable HPG axis activation; measurable testosterone/LH improvement on bloodwork; improved reproductive parameters
Long-Term
Must maintain pulsatile dosing to avoid desensitization; promising IVF trigger data; long-term reproductive axis support
What Does the Research Say?
The following are key findings from peer-reviewed studies on Kisspeptin-10, indexed on PubMed and equivalent databases:
[1]Kisspeptin potently stimulates LH and testosterone in healthy men
Dhillo et al. (J. Clin. Endocrinol. Metab.): IV Kisspeptin-10 (1mcg/kg) potently stimulates LH pulse frequency and testosterone secretion in healthy men, establishing its role as a reproductive axis activator.
Evidence: moderate[2]Kisspeptin restores LH pulsatility in hypogonadal men
George et al.: Kisspeptin-10 infusion restores LH pulsatility and increases testosterone in men with type 2 diabetes-associated hypogonadism, demonstrating therapeutic potential.
Evidence: moderate[3]Kisspeptin as alternative oocyte maturation trigger in IVF
Abbara et al. (J. Clin. Invest.): Kisspeptin-54 triggers oocyte maturation in women undergoing IVF with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) vs. hCG trigger.
Evidence: strong[4]Kisspeptin stimulates reproductive hormones in women
Jayasena et al.: Kisspeptin-10 administration increases LH secretion in women, with response magnitude dependent on menstrual cycle phase (strongest in preovulatory phase).
Evidence: moderate[5]Kisspeptin tachyphylaxis with continuous administration
Ramaswamy et al.: Continuous Kisspeptin-10 infusion leads to desensitization of the HPG axis within 24-48 hours, indicating pulsatile dosing protocols are necessary for sustained efficacy.
Evidence: preclinicalSafety & Side Effects
Endogenous human neuropeptide with growing clinical trial data. Tachyphylaxis (desensitization) occurs with continuous dosing; pulsatile/intermittent protocols required. Being investigated as a safer IVF trigger (vs. hCG). Not FDA-approved for therapeutic use. Research-only.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~8% of users | mild |
| Mild headache | ~5% of users | mild |
| Flushing / warmth | ~5% of users | mild |
| Tachyphylaxis (with continuous dosing) | Variable | moderate |
FDA Status: Not Approved for Human Therapeutic Use
Kisspeptin-10 is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is Kisspeptin-10 Used?
Route
SubQ
Dose Range
100–100 mcg
Frequency
3x/wk
Cycle
8–8 wk
Timing: Morning or split AM/PM
Notes: Pulsatile dosing critical: continuous administration causes desensitization within 24-48 hours. Clinical studies use 1mcg/kg IV or 100-400mcg SubQ. Cycle 5 days on / 2 days off to prevent tachyphylaxis. Monitor LH, FSH, testosterone/estradiol on bloodwork.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Kisspeptin-10 vs. Related Compounds
| Compound | Primary Use |
|---|---|
| Kisspeptin-10(this page) | LH/FSH stimulation, testosterone support, fertility enhancement, HPG axis activation |
| CJC-1295 | Muscle growth, fat loss, recovery |
| Ipamorelin | GH release, muscle growth, recovery without cortisol spike |
Where to Source Kisspeptin-10 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Kisspeptin-10?
Kisspeptin-10 is a reproductive peptide peptide. Endogenous neuropeptide that is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin-10 binds to the GPR54 (KISS1R) receptor on GnRH neurons, triggering pulsatile GnRH release which stimulates LH and FSH secretion from the pituitary. This cascade drives testosterone production in males and ovulation in females. Unique advantage: activates the reproductive axis at its highest control point without bypassing natural feedback loops.
What are the primary research benefits of Kisspeptin-10?
Published research identifies primary mechanisms targeting: LH/FSH stimulation, testosterone support, fertility enhancement, HPG axis activation. These findings come from 5+ peer-reviewed studies indexed in our database.
What is the half-life of Kisspeptin-10?
In published pharmacokinetic data, Kisspeptin-10 demonstrates a half-life of approximately 0.5 hours.
Is Kisspeptin-10 FDA approved?
Kisspeptin-10 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of Kisspeptin-10?
Reported side effects in published literature include Injection site reaction (~8% of users), Mild headache (~5% of users), Flushing / warmth (~5% of users), Tachyphylaxis (with continuous dosing) (Variable). Most are classified as mild in severity.
How is Kisspeptin-10 administered?
In research settings, Kisspeptin-10 is typically administered via SubQ. Pulsatile dosing critical: continuous administration causes desensitization within 24-48 hours. Clinical studies use 1mcg/kg IV or 100-400mcg SubQ. Cycle 5 days on / 2 days off to prevent tachyphylaxis. Monitor LH, FSH, testosterone/estradiol on bloodwork.
Sources
- Kisspeptin potently stimulates LH and testosterone in healthy men. View on PubMed
- Kisspeptin restores LH pulsatility in hypogonadal men. View on PubMed
- Kisspeptin as alternative oocyte maturation trigger in IVF. View on PubMed
- Kisspeptin stimulates reproductive hormones in women. View on PubMed
- Kisspeptin tachyphylaxis with continuous administration. View on PubMed